Sustiva smpc

Common Questions and Answers about Sustiva smpc

sustiva

Avatar f tn I am 52 years old postmenopausal 1 yr and 2 months. I have an endometrial lining of 14.95 and 2 fibroids that are each 2cm. each. How concerned should I be that this is cancer? Anyone else have anything similar to this?
Avatar f tn I've had HIV for several years, luckily it was caught early. I started meds fairly soon after. I started Atripla in 2010. It got be undetectable quickly and has kept that way. I never had major bad side effects on it. I did have some crazy dreams and still do. After I was on it for a couple years, things began to slowly deteriorate. I began getting panic attacks, and bouts of tachycardia and palpitations. I had a history of those but it seemed to get worse.
Avatar m tn hello there,we're on thesame regimen.i recently changed from sustiva to norvir,truvada and reyetaz.i've been on this for 8months now but no s/e.i had uti once,but that's about it.what was ur cd4 count before u got on the meds?
Avatar m tn In June 2005 I tested positive with a VL of 330,000 and antibody test at this time it was non react which for what I have read is negative for the antibodies, I decided back then to start treatment right away (Truvada & Sustiva) due to the high VL, I got a geno and phenotype test done before starting treatment, Dr.
Avatar m tn I haven't yet found reason for my symptoms. I have negative HIV antibody test result at 16 weeks mark and still have palpable lymph nodes in my neck,under jaw and in my groins. I had a rash on my forehead after exposure and my girlfriend has the same rash now. She also has persistent headaches and stomach aches. I am so scared especially when I see cases like this from the Body: False positive or false negative?
Avatar m tn Furthermore, the applicant has requested that the use of daclatsvir with pegIFN/RBV, as used in the AI444042 study, be cited as a recommended regimen in section 4.2. of the SmPC. While the, relatively speaking, inferior safety profile of interferon-based regimens is recognised, the efficacy data from this study, along with the totality of the safety database for daclatasvir when used with pegIFN/RBV, is supportive of this proposal.